Drug Profile
ASN 001
Alternative Names: ASN001Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Asana BioSciences
- Class Antineoplastics
- Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 07 Mar 2018 Asana BioSciences terminates a phase-I/II trial in Prostate cancer (Hormone refractory, Metastatic disease) in USA due to a business decision (NCT02349139)
- 05 Sep 2017 Phase-I/II development is ongoing for Prostate cancer (Hormone refractory, Metastatic disease) in USA (NCT02349139)
- 02 Jun 2017 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I/II trial in Prostate cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)